Cargando…
Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
The participation of proinflammatory cytokines in the progression of Multiple Sclerosis (MS) has been well documented. Cytokines activate the JAK-STAT pathway, in which the suppressors of cytokine signaling (SOCS) exert a negative feedback. This paper analyzes the levels of SOCS5 and SOCS7 transcrip...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982240/ https://www.ncbi.nlm.nih.gov/pubmed/31905601 http://dx.doi.org/10.3390/ijms21010218 |
_version_ | 1783491269724471296 |
---|---|
author | Rojas-Morales, Emmanuel Santos-López, Gerardo Hernández-Cabañas, Samuel Arcega-Revilla, Raúl Rosas-Murrieta, Nora Jasso-Miranda, Carolina El-Kassis, Elie Girgis Reyes-Leyva, Julio Sedeño-Monge, Virginia |
author_facet | Rojas-Morales, Emmanuel Santos-López, Gerardo Hernández-Cabañas, Samuel Arcega-Revilla, Raúl Rosas-Murrieta, Nora Jasso-Miranda, Carolina El-Kassis, Elie Girgis Reyes-Leyva, Julio Sedeño-Monge, Virginia |
author_sort | Rojas-Morales, Emmanuel |
collection | PubMed |
description | The participation of proinflammatory cytokines in the progression of Multiple Sclerosis (MS) has been well documented. Cytokines activate the JAK-STAT pathway, in which the suppressors of cytokine signaling (SOCS) exert a negative feedback. This paper analyzes the levels of SOCS5 and SOCS7 transcripts, quantified by RT-qPCR, in MS patients, and the concentrations of proinflammatory cytokines, IFN-γ, IL17, and IL6, determined by ELISA. Samples of peripheral blood were obtained from MS patients in the relapsing–remitting phase, treated with IFN-β or glatiramer acetate (GA), and from healthy individuals. SOCS7 mRNA was significantly higher in patients treated with GA (1.36 ± 0.23) than in those treated with IFN-β (0.65 ± 0.1). Regarding gender, the level of SOCS5 and SOCS7 transcripts were similar between MS and healthy females; in MS males, the level of SOCS7 transcripts were significantly lower (0.59 ± 0.03) than in healthy males (1.008 ± 0.05). Plasmatic levels of IFN-γ were significantly higher in MS patients (60 pg/mL, range 0–160) than in healthy subjects (0 range, 0–106). The same pattern was observed in MS patients treated with IFN-β (68 pg/mL, range 0–160) compared to patients treated with GA (51 pg/mL, range 0–114), and in MS females (64 pg/mL, range 0–161) compared to healthy females (0, range 0–99). We hypothesize that the increase in SOCS7 transcription in patients treated with GA could partially explain the action mechanism of this drug, while the increase in the concentration of IFN-γ in MS patients could help elucidate the immunopathology of the disease. |
format | Online Article Text |
id | pubmed-6982240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69822402020-02-07 Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate Rojas-Morales, Emmanuel Santos-López, Gerardo Hernández-Cabañas, Samuel Arcega-Revilla, Raúl Rosas-Murrieta, Nora Jasso-Miranda, Carolina El-Kassis, Elie Girgis Reyes-Leyva, Julio Sedeño-Monge, Virginia Int J Mol Sci Article The participation of proinflammatory cytokines in the progression of Multiple Sclerosis (MS) has been well documented. Cytokines activate the JAK-STAT pathway, in which the suppressors of cytokine signaling (SOCS) exert a negative feedback. This paper analyzes the levels of SOCS5 and SOCS7 transcripts, quantified by RT-qPCR, in MS patients, and the concentrations of proinflammatory cytokines, IFN-γ, IL17, and IL6, determined by ELISA. Samples of peripheral blood were obtained from MS patients in the relapsing–remitting phase, treated with IFN-β or glatiramer acetate (GA), and from healthy individuals. SOCS7 mRNA was significantly higher in patients treated with GA (1.36 ± 0.23) than in those treated with IFN-β (0.65 ± 0.1). Regarding gender, the level of SOCS5 and SOCS7 transcripts were similar between MS and healthy females; in MS males, the level of SOCS7 transcripts were significantly lower (0.59 ± 0.03) than in healthy males (1.008 ± 0.05). Plasmatic levels of IFN-γ were significantly higher in MS patients (60 pg/mL, range 0–160) than in healthy subjects (0 range, 0–106). The same pattern was observed in MS patients treated with IFN-β (68 pg/mL, range 0–160) compared to patients treated with GA (51 pg/mL, range 0–114), and in MS females (64 pg/mL, range 0–161) compared to healthy females (0, range 0–99). We hypothesize that the increase in SOCS7 transcription in patients treated with GA could partially explain the action mechanism of this drug, while the increase in the concentration of IFN-γ in MS patients could help elucidate the immunopathology of the disease. MDPI 2019-12-28 /pmc/articles/PMC6982240/ /pubmed/31905601 http://dx.doi.org/10.3390/ijms21010218 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rojas-Morales, Emmanuel Santos-López, Gerardo Hernández-Cabañas, Samuel Arcega-Revilla, Raúl Rosas-Murrieta, Nora Jasso-Miranda, Carolina El-Kassis, Elie Girgis Reyes-Leyva, Julio Sedeño-Monge, Virginia Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate |
title | Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate |
title_full | Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate |
title_fullStr | Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate |
title_full_unstemmed | Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate |
title_short | Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate |
title_sort | differential transcription of socs5 and socs7 in multiple sclerosis patients treated with interferon beta or glatiramer acetate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982240/ https://www.ncbi.nlm.nih.gov/pubmed/31905601 http://dx.doi.org/10.3390/ijms21010218 |
work_keys_str_mv | AT rojasmoralesemmanuel differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT santoslopezgerardo differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT hernandezcabanassamuel differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT arcegarevillaraul differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT rosasmurrietanora differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT jassomirandacarolina differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT elkassiseliegirgis differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT reyesleyvajulio differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate AT sedenomongevirginia differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate |